BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Clinical Trials Arena: HighField Bio initiates its glioma trial with first patient dosing
Biospace: HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
